ATE343374T1 - Fluticasonpropionat arzneizubereitung - Google Patents

Fluticasonpropionat arzneizubereitung

Info

Publication number
ATE343374T1
ATE343374T1 AT00958854T AT00958854T ATE343374T1 AT E343374 T1 ATE343374 T1 AT E343374T1 AT 00958854 T AT00958854 T AT 00958854T AT 00958854 T AT00958854 T AT 00958854T AT E343374 T1 ATE343374 T1 AT E343374T1
Authority
AT
Austria
Prior art keywords
fluticasone propionate
medicinal preparation
formulation
fluticasone
propionate
Prior art date
Application number
AT00958854T
Other languages
English (en)
Inventor
Alan Leslie Cripps
Paul Johnson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27255761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE343374(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9921396.9A external-priority patent/GB9921396D0/en
Priority claimed from GB0014451A external-priority patent/GB0014451D0/en
Priority claimed from GB0018654A external-priority patent/GB0018654D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE343374T1 publication Critical patent/ATE343374T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AT00958854T 1999-09-11 2000-09-11 Fluticasonpropionat arzneizubereitung ATE343374T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9921396.9A GB9921396D0 (en) 1999-09-11 1999-09-11 Pharmaceutical formulation
GB0014451A GB0014451D0 (en) 2000-06-13 2000-06-13 Pharmaceutical formulation
GB0018654A GB0018654D0 (en) 2000-07-28 2000-07-28 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ATE343374T1 true ATE343374T1 (de) 2006-11-15

Family

ID=27255761

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00958854T ATE343374T1 (de) 1999-09-11 2000-09-11 Fluticasonpropionat arzneizubereitung

Country Status (12)

Country Link
US (4) US6479035B1 (de)
EP (1) EP1143930B8 (de)
JP (1) JP2003509359A (de)
AT (1) ATE343374T1 (de)
AU (1) AU7026800A (de)
CA (1) CA2317999C (de)
DE (1) DE60031504T2 (de)
ES (1) ES2274803T3 (de)
FR (4) FR2798290B1 (de)
GB (1) GB2354007B (de)
IT (1) IT1317904B1 (de)
WO (1) WO2001019342A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814717D0 (en) * 1998-02-23 1998-09-02 Bespak Plc Improvements in drug delivery devices
CA2317999C (en) * 1999-09-11 2004-11-09 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
EP1248597B1 (de) * 1999-12-24 2005-03-30 Glaxo Group Limited Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (de) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Betätigungsvorrichtung für Druckdosierinhalator mit lasergebohrten Löchern
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
IL163843A0 (en) * 2002-03-01 2005-12-18 Chiesi Farma Spa Formoterol superfine formulation
EP1340492A1 (de) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US8338594B2 (en) * 2005-12-02 2012-12-25 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
EP2482822B1 (de) 2009-10-01 2018-08-01 Adare Pharmaceuticals, Inc. Oral verabreichte corticosteroid-zusammensetzungen
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
CN102379846B (zh) * 2011-10-21 2014-07-02 江苏长风药业有限公司 以氢氟烷烃和聚乙二醇为辅料氟替卡松丙酸酯气雾剂制剂
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
CN107880091B (zh) 2012-05-08 2020-12-18 尼科斯眼药公司 疏水性治疗剂的制剂、其制备方法及应用
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP3797964B1 (de) 2019-09-26 2023-06-07 Presspart Manufacturing S.A. Spritzgiesswerkzeug für inhalator abgemessener dosen
WO2021216779A1 (en) * 2020-04-21 2021-10-28 Amphastar Pharmaceuticals, Inc. Anti-viral pharmaceutical formulations administered via devices for lung targeted delivery
US12514995B2 (en) 2021-02-15 2026-01-06 Glenmark Pharmaceuticals Limited Metered dose inhalers of fluticasone or an ester thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL289785A (de) * 1962-11-29
CH634480A5 (de) * 1977-11-25 1983-02-15 Schwarzkopf Gmbh Hans Unter druck stehendes aerosolpraeparat.
DE2949933A1 (de) 1979-12-12 1981-06-19 Wabco Fahrzeugbremsen Gmbh, 3000 Hannover Vorrichtung zum verhindern von schlingerbewegungen eines anhaengers
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB2235627B (en) 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
AU658854B2 (en) 1990-10-18 1995-05-04 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
ATE128350T1 (de) 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
EP0673240B1 (de) 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilisierte medizinische aerosollösungen
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
BR9604978A (pt) 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador com dose medida
JP2001505171A (ja) 1996-12-04 2001-04-17 バイオグラン アイルランド（アール アンド ディ）リミテッド 製薬組成物及びその投与のための装置
DK1014943T3 (da) * 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
CA2329900A1 (en) 1998-04-30 1999-11-04 3M Innovative Properties Company Metered-dose valve for pharmaceutical aerosol
KR100600423B1 (ko) 1998-06-18 2006-07-13 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 2개 이상의 활성 물질을 포함하는 연무질 약제학적 제형
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6231519B1 (en) * 1999-05-04 2001-05-15 Nokia Corporation Method and apparatus for providing air quality analysis based on human reactions and clustering methods
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
CA2317999C (en) * 1999-09-11 2004-11-09 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
EP1523976A3 (de) 1999-11-23 2005-06-22 Glaxo Group Limited Pharmazeutische Formulierungen enthaltend Salmeterol
GB0002798D0 (en) 2000-02-09 2000-03-29 Glaxo Group Ltd Actuator nozzle for metered dose inhaler

Also Published As

Publication number Publication date
FR2843882B1 (fr) 2011-04-22
FR2848453B1 (fr) 2010-09-03
US20040037783A1 (en) 2004-02-26
WO2001019342A3 (en) 2001-08-09
FR2843882A1 (fr) 2004-03-05
GB0022222D0 (en) 2000-10-25
ES2274803T3 (es) 2007-06-01
ITRM20000491A0 (it) 2000-09-11
EP1143930A3 (de) 2002-09-11
CA2317999C (en) 2004-11-09
FR2798290B1 (fr) 2003-09-12
JP2003509359A (ja) 2003-03-11
AU7026800A (en) 2001-04-17
US20030086876A1 (en) 2003-05-08
US6630129B2 (en) 2003-10-07
EP1143930B8 (de) 2008-03-19
DE60031504D1 (de) 2006-12-07
EP1143930A2 (de) 2001-10-17
CA2317999A1 (en) 2001-03-11
FR2820322A1 (fr) 2002-08-09
US6479035B1 (en) 2002-11-12
DE60031504T2 (de) 2007-04-05
GB2354007B (en) 2003-10-22
IT1317904B1 (it) 2003-07-15
WO2001019342A2 (en) 2001-03-22
EP1143930B1 (de) 2006-10-25
GB2354007A (en) 2001-03-14
FR2798290A1 (fr) 2001-03-16
US20040157815A1 (en) 2004-08-12
FR2820322B1 (fr) 2005-03-11
ITRM20000491A1 (it) 2002-03-11
FR2848453A1 (fr) 2004-06-18
US7220403B2 (en) 2007-05-22

Similar Documents

Publication Publication Date Title
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
DE60019167D1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
PT1037604E (pt) Composicoes farmaceuticas de aerossol
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
DE60308997D1 (de) Formulierungen zur inhalation
NZ298169A (en) Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
EP1135173A4 (de) Medikamenthaltige zusammensetzung in aerosolform
DK0918507T3 (da) Aerosolformuleringer
JO2381B1 (en) Formulation containing anticholinergic drug for the treatment of chronic obstructive pulmonary disease
GB0016876D0 (en) Novel formulation
MXPA03001752A (es) Uso de la combinacion de salmeterol y propionato de fluticasona.
WO2002007672A3 (en) A medicinal aerosol formulation
ATE286716T1 (de) Pharmazeutische formulierungen enthaltend salmeterol
CA2446562A1 (en) Pharmaceutical formulation of fluticasone propionate
AU2003300230A1 (en) Dosing aerosols containing lecithin as a surface-active substance

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties